Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals during the fourth quarter of 2025. The estimated value of the shares sold was $8.18 million, calculated using the average closing price for the quarter. The quarter-end value of the fund’s Syndax position increased by $38.07 million, a figure that captures both trading and share price movements.

Kynam Capital Management’s Syndax position was reduced, now accounting for 10.81% of reportable 13F assets under management following the sale.

Top holdings after the filing:

NASDAQ:COGT: $218.99 million (14.3% of AUM)

NASDAQ:VERA: $173.85 million (11.3% of AUM)

NASDAQ:SNDX: $169.15 million (11.0% of AUM)

NASDAQ:CLDX: $161.42 million (10.5% of AUM)

NASDAQ:PCVX: $134.84 million (8.8% of AUM)

As of Friday, shares of Syndax Pharmaceuticals were priced at $24.23, up 72% over the past year and well outperforming the S&P 500’s roughly 15% gain in the same period.

Metric

Value

Price (as of Friday)

$24.23

Market capitalization

$2.1 billion

Revenue (TTM)

$172.4 million

Net income (TTM)

($285.4 million)

Syndax Pharmaceuticals develops oncology therapies, including SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease, with additional pipeline assets such as Entinostat.

The firm operates a clinical-stage biopharmaceutical model, generating revenue primarily through research collaborations, licensing agreements, and milestone payments.

It targets healthcare providers, research institutions, and pharmaceutical partners focused on innovative cancer treatments and rare disease therapies.

Syndax Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in the development of novel cancer therapies. The company leverages a focused pipeline strategy aimed at high-need oncology indications, supported by strategic collaborations and licensing agreements. Its emphasis on targeted therapies and partnerships positions it to address unmet medical needs in hematologic malignancies and immune-related disorders.

It’s not surprising that a fund would make a transaction like this, cutting some shares but holding onto a still-substantial stake. Syndax generated about $172 million in total revenue last year, driven by growing uptake of its recently launched therapies, including roughly $124.8 million from Revuforj and a meaningful contribution from its Niktimvo collaboration. That kind of commercial traction is rare for companies at this stage, and it helps explain why the stock has surged more than 70% over the past year.

At the same time, the business is still burning cash, with a full-year net loss of about $285 million and elevated operating expenses tied to R&D and commercialization. That tension between growth and profitability is exactly where active managers tend to rebalance rather than fully exit.

Plus, within a portfolio heavily concentrated in biotech names like Cogent and Vera, this looks like a measured adjustment rather than a shift in thesis. The position still accounts for more than 10% of assets, after all, signaling continued conviction.

Before you buy stock in Syndax Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Syndax Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*

Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 21, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish was originally published by The Motley Fool